The aim of the study is to apply a novel clinical investigation protocol in patients with Phosphodiesterase 6A (PDE6A), PDE6B and Rhodopsin (RHO)-based retinitis pigmentosa. This novel, multimodal clinical examination protocol describes and correlates structural, functional and metabolic aspects during natural disease development.
Test-retest variability of new measurements as well as correlations of the structural, functional, and metabolic changes will be defined to be able to define well-suited readouts for safety and efficacy of future treatment developments before they reach the clinical phase.
Eligibility
Sex
ALL
Min age
5 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age: from 5 years of age
* Patient with PDE6A, PDE6B, and RHO-based retinitis pigmentosa
* Patient and/or legal representatives are willing and able to give written informed consent
Exclusion Criteria:
* severe general disease, that would make longer examinations not possible
Primary outcome measure(s)
Optical coherence tomography (OCT) — 3-5 years OCT volume scans of the macular region, morphological examination
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.